This Trial is a Clinical Performance Validation Study That Will Evaluate the Clinical Agreement of the Sky Medical™ Rapid Antigen Test Comparing the Antigen Rapid Test to RT-PCR

COVID-19 Clinical Trial

Official title:

Clinical Evaluation of the Sky Medical™ Rapid Diagnostic Test for Detection of SARS-CoV-2 Antigen

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05491993
• Other study ID #: SKYCOV001-2
• Status: Recruiting
• Phase: N/A
• Start date: February 22, 2022
• Est. completion date: January 11, 2023

Study information

• Verified date: August 2022
• Source: Sky Medical Supplies & Equipments, LLC
• Contact: Mariana-Kathryn LaParl
• Phone: (954)804-3760
• Email: MarianaLaParl[@]skymedical.us
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospective study that will evaluate the clinical agreement of the Sky Medical™ Rapid Antigen Test compared to SARS-CoV-2 RT-PCR.

Description:

Clinical performance characteristics of the Sky Medical™SARS-CoV-2 Antigen Rapid test was compared to a Reference Extracted EUA SARS-CoV-2 RT-PCR. The test kit was evaluated in the U.S in which patients were sequentially enrolled and tested. Symptomatic subjects were enrolled within six days of the onset of symptoms from a multi-site prospective clinical study. A total of 69 Nasopharyngeal samples, were tested in one (1) CLIA waived investigational site by five (5) minimally trained operators in the U.S during the 2022 COVID-19 season.

NP swab specimens collected from the patients with COVID-19 like symptoms in the U.S during the 2022 COVID-19 season and stored in BD universal transport media tube were provided by our site in the U.S. All the NP swab specimens were confirmed as positive or negative and validated with Ct value by the FDA EUA RT-PCR as a comparator method prior to the study. A total of 69 samples consisting of 39 confirmed positive nasopharyngeal (NP) swabs, 30 confirmed negative NP swab specimens were collected. The specimens were aliquoted, randomized, and blinded into sample panels that were tested by each operator, using the instructions provided by the Quick Reference Instructions (QRI).

All the study samples were randomized and assigned with a unique study subject ID by the sponsor prior to testing at the study site. The expected results of the samples were completely blinded to the operators. All the samples were tested by five (5) operators according to the Quick Reference Instructions only.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: January 11, 2023
• Est. primary completion date: January 11, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 7 Years and older

Eligibility

Inclusion Criteria:

• Provision of informed consent.

• Subject is suspected case of COVID-19 by clinical criteria: a patient with acute respiratory tract infection (sudden onset of at least one of the following: cough, fever, shortness of breath, fatigue, decreased appetite, myalgia) AND with no other etiology that fully explains the clinical presentation, with or without a history of close contact with a confirmed or probable COVID-19 case in the last 14 days prior to onset of symptoms.

• Subject is an appropriate candidate for Nasopharyngeal sample collection.

• Subject is willing to provide Nasopharyngeal samples.

Exclusion Criteria:

• Individuals who present with 10 or greater days of Covid-19 Related Symptoms, (Fever, Cough, Fatigue, Decreased Appetite, Shortness of Breath, Myalgia) or post- defervescence and/or convalescence.

Related Conditions & MeSH terms

• COVID-19
• Sars-CoV-2 Infection

Intervention

Diagnostic Test:
• Sky Medical™ Rapid Antigen Test
Rapid Antigen Diagnostic Test device performance comparative to RT-PCR.

Locations

Country	Name	City	State
United States	American Research Labs	Lake Worth	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Sky Medical Supplies & Equipments, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent Positive Agreement and Negative Percent Agreement	Calculate the performance of the Rapid Antigen Test compared to PCR using swab samples.	90 Days